Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Cohort Study to Monitor and Compare the Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Dolutegravir (With and Without Abacavir) or Other Integrase Inhibitors (With or Without Abacavir)

NCT03327740 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT03327740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03327740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Cohort Study to Monitor and Compare the Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Dolutegravir (With and Without Abacavir) or Other Integrase Inhibitors (With or Without Abacavir)
Lead sponsor
ViiV Healthcare
Phase
Observational
Overall status
Completed
Start date
September 30, 2014
Completion date
December 31, 2019
Enrollment
1 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus i